年龄相关性黄斑变性的发病率及相关危险因素:ALIENOR 研究四年随访
该基于法国波尔多 73 岁及以上人群的队列研究纳入 659 名受试者,平均随访 3.8 年。早期 AMD 发病率为每 1000 人年 79.9,晚期为 18.6,5 年风险分别为 32.9% 和 8.9%。早期向晚期进展与对侧眼 AMD 分级、吸烟至少 20 包年及 CFH Y402H 基因型相关。
要点
- 早期与晚期 AMD 发病率分别为每 1000 人年 79.9 和 18.6。
- 早期 AMD 发病与对侧眼早期 AMD 及高血浆高密度脂蛋白胆固醇水平相关。
- 早期向晚期进展与对侧眼 AMD 分级、吸烟至少 20 包年及 CFH Y402H 基因型相关。
核心结论
- 该队列中 AMD 发病率与其他欧洲人群相似。
- 研究提示高血浆高密度脂蛋白胆固醇水平者发生早期 AMD 风险高。
- 研究证实重度吸烟者及携带 CFH Y402H 风险基因型者早期向晚期 AMD 进展风险高。
研究设计与样本
- 基于人群的队列研究,纳入法国波尔多 963 名 73 岁及以上居民,基线参与 ALIENOR 研究时间为 2006 年 10 月 2 日至 2012 年 12 月 21 日。
- 829 名有发生 AMD 风险的参与者中,659 名(79.5%)接受了平均(SD)3.8(1.1)年的随访观察。
- 数据分析时间为 2016 年 8 月至 2017 年 3 月。
主要发现
- 659 名合格参与者中 413 名(62.7%)为女性,平均(SD;范围)年龄 79.7(4.4;73-94)岁。
- 共记录 120 例新发早期 AMD 和 45 例新发晚期 AMD。
- 早期和晚期 AMD 发病率分别为每 1000 人年 79.9(95%CI,66.8-95.5)和 18.6(95%CI,13.9-24.9),对应 5 年风险分别为 32.9% 和 8.9%。
- 晚期 AMD 每 1000 眼年发病率在基线无 AMD 眼为 1.5,早期 AMD1 眼为 42.4,早期 AMD2 眼为 85.1。
- 多因素分析(未校正多重检验)中,早期向晚期 AMD 进展与对侧眼 AMD 分级(风险比[HR]随分级为 13.0[95%CI,2.8-61.2]至 22.5[95%CI,2.6-195.9])、吸烟至少 20 包年(HR,3.0;95%CI,1.4-6.5)及补体因子 H(CFH)Y402H 基因型(CC 基因型:HR,2.3;95%CI,1.0-5.3;TC 基因型:HR,1.5;95%CI,0.6-3.7)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While the prevalence of age-related macular degeneration (AMD) differs according to continents and races/ethnicities, its incidence in the European continent has been scarcely documented. OBJECTIVE: To describe the incidence and associated risk factors of AMD in elderly French individuals. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of 963 residents of Bordeaux, France, who were 73 years or older at baseline and participated in the Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires (ALIENOR) Study between October 2, 2006, and December 21, 2012. Of 829 participants at risk for incident AMD, 659 (79.5%) were observed for a mean (SD) duration of 3.8 (1.1) years. Data were analyzed from August 2016 to March 2017. MAIN OUTCOMES AND MEASURES: Age-related macular degeneration was graded from retinal photographs and spectral-domain optical coherence tomography into 5 exclusive stages: no AMD, early AMD1, early AMD2, late atrophic AMD, and late neovascular AMD. RESULTS: Of the 659 eligible participants, 413 (62.7%) were women, and the mean (SD; range) age was 79.7 (4.4; 73-94) years. A total of 120 incident cases of early AMD and 45 incident cases of advanced AMD were recorded. Incidence rates of early and advanced AMD were 79.9 (95% CI, 66.8-95.5) per 1000 person-years and 18.6 (95% CI, 13.9-24.9) per 1000 person-years, respectively, corresponding to 5-year risks of 32.9% and 8.9%. Incidence of advanced AMD per 1000 eye-years was 1.5 in eyes without any AMD at baseline, 42.4 in those with early AMD1, and 85.1 in those with early AMD2. In multivariate analysis without correction for multiple testing, progression from early to advanced AMD was associated with AMD grade in the fellow eye (hazard ratio [HR] according to grade, 13.0 [95% CI, 2.8-61.2] to 22.5 [95% CI, 2.6-195.9]), having smoked at least 20 pack-years (calculated as number of smoking years × mean number of cigarettes per day / 20; HR, 3.0; 95% CI, 1.4-6.5), and complement factor H (CFH) Y402H genotype (CC genotype: HR, 2.3; 95% CI, 1.0-5.3; TC genotype: HR, 1.5; 95% CI, 0.6-3.7). Incidence of early AMD was associated with early AMD in the fellow eye (early AMD1: HR, 2.6; 95% CI, 1.6-4.2; early AMD2: HR, 5.6; 95% CI, 3.3-9.4) and high plasma high-density lipoprotein cholesterol levels (HR, 1.2; 95% CI, 1.0-1.4). CONCLUSIONS AND RELEVANCE: In this cohort, AMD incidence rates were similar to those observed in other European populations. This study suggests a high risk for incident early AMD in individuals with high plasma high-density lipoprotein cholesterol levels while confirming the high risk for progression from early to advanced AMD in heavy smokers and carriers of CFH Y402H at-risk genotypes.
引用
- Saunier V, Merle BMJ, Delyfer MN, et al. Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study. JAMA Ophthalmol. 2018. PMID: 29596588. doi:10.1001/jamaophthalmol.2018.0504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。